Payment overview · 2025
General Payments
$2,961.52
128 reported records · 34 companies
Healthcare provider profile · identity verified
Tarra Mccullar Nelson, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · CUMMING, GA · NPI 1295722973
Verified facts
What the public records show
CMS Open Payments records show Tarra Mccullar Nelson, NP-C received $2,961.52 in general payments during 2025 across 128 reported records.
UCB, Inc. accounted for 13.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rytary by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Gocovri by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $400.43 | 13.5% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $315.97 | 10.7% | 18 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $261.99 | 8.8% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $260.96 | 8.8% | 22 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $254.60 | 8.6% | 12 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $245.85 | 8.3% | 7 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $99.99 | 3.4% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$99.85 | 3.4% | 3 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $97.23 | 3.3% | 4 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $86.58 | 2.9% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $81.73 | 2.8% | 3 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $77.53 | 2.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $70.50 | 2.4% | 3 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $57.02 | 1.9% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $51.06 | 1.7% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.16 | 1.7% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $48.77 | 1.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.84 | 1.3% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $37.15 | 1.2% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $28.71 | 1.0% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.50 | 1.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.05 | 0.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $26.82 | 0.9% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $22.33 | 0.8% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $22.20 | 0.8% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $21.32 | 0.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.09 | 0.7% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $20.30 | 0.7% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $20.14 | 0.7% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$19.72 | 0.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.11 | 0.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.94 | 0.6% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $17.61 | 0.6% | 1 | 2025 |
| OWP Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.47 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,861.53 | 127 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $254.60 | 12 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $245.85 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $229.72 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $172.00 | 18 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $172.00 | 18 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $166.58 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $121.86 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc., PFIZER INC. | $114.96 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $111.64 | 11 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $97.23 | 4 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $92.06 | 5 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $86.58 | 3 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $83.56 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $81.73 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $81.73 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $79.59 | 3 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $77.53 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $70.50 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $52.81 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $51.06 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $49.16 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $48.77 | 2 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $42.73 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $28.94 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $27.42 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $27.05 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $26.82 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| Subvenite Normalized: subvenite |
Drug | OWP Pharmaceuticals, Inc. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $5.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 392 | 108 |
| Donepezil Hcl | Donepezil Hcl | 283 | 89 |
| Duloxetine Hcl | Duloxetine Hcl | 253 | 85 |
| Gabapentin | Gabapentin | 202 | 72 |
| Memantine Hcl Er | Memantine Hcl | 199 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 144 | 36 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 132 | 30 |
| Cilostazol | Cilostazol | 127 | 45 |
| Trazodone Hcl | Trazodone Hcl | 119 | 38 |
| Levetiracetam | Levetiracetam | 111 | 19 |
| Pregabalin | Pregabalin | 107 | 33 |
| Topiramate | Topiramate | 85 | 30 |
| Rasagiline Mesylate | Rasagiline Mesylate | 79 | 19 |
| Mirtazapine | Mirtazapine | 74 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 22 |
| Bupropion Xl | Bupropion Hcl | 69 | 12 |
| Baclofen | Baclofen | 67 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 21 |
| Austedo | Deutetrabenazine | 63 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 16 |
| Lacosamide | Lacosamide | 59 | 18 |
| Imipramine Hcl | Imipramine Hcl | 56 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 56 | 13 |
| Clonazepam | Clonazepam | 55 | 15 |
| Primidone | Primidone | 54 | 18 |
| Amantadine | Amantadine Hcl | 44 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | suppressed |
| Briviact | Brivaracetam | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | 14 |
| Rivastigmine | Rivastigmine | 37 | 11 |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Droxidopa | Droxidopa | 35 | suppressed |
| Lorazepam | Lorazepam | 31 | 15 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | 11 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 29 | suppressed |
| Zonisamide | Zonisamide | 29 | 13 |
| Midodrine Hcl | Midodrine Hcl | 28 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Ubrelvy | Ubrogepant | 25 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | 12 |
| Eliquis | Apixaban | 19 | suppressed |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 18 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Gocovri | Amantadine Hcl | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Neupro | Rotigotine | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Rytary | Carbidopa/Levodopa | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Dipyridamole | Dipyridamole | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,961.52 · 128 records | UCB, Inc. | AMYVID, AUSTEDO XR, AVONEX, Briviact, CREXONT, EMGALITY, EPIDIOLEX, FYCOMPA, Fintepla, GOMEKLI, HYQVIA, Hizentra, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, PRECIVITYAD2, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Rystiggo, SPRAVATO, Subvenite, Symbravo, TYSABRI, UBRELVY, UPLIZNA, VALTOCO, VRAYLAR, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAKIX, Xeomin, ZAVZPRET, Zilbrysq | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error